cardiovascular

News

Person with blood pressure cuff on their arm

AZ uses a priority review voucher for baxdrostat filing

Seeking a lead over rival Mineralys, AstraZeneca is using a priority review voucher for its US filing for uncontrolled hypertension drug baxdrostat.

R&D

pharmaphorum podcast Episode 221, Sandeep Kulkarni, Tourmaline Bio

On inflammation, heart health, and GLP-1 possibilities, with...

Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.

News

AHA: Cash for drug adherence study has disappointing result

People with hypertension were twice as likely to take medicine regularly when offered cash rewards, but that didn't improve their blood pressure.

News

Novartis nabs cardio drug with $1.4bn Tourmaline buy

Novartis has bulked up in cardiology with a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).

News

AZ extends cardiovascular pipeline with $2bn CSPC deal

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut

News

Cytokinetics eyes go-it-alone strategy for aficamten

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financi

AZ uses a priority review voucher for baxdrostat filing

On inflammation, heart health, and GLP-1 possibilities, with...

AHA: Cash for drug adherence study has disappointing result

Novartis nabs cardio drug with $1.4bn Tourmaline buy

AZ extends cardiovascular pipeline with $2bn CSPC deal

Cytokinetics eyes go-it-alone strategy for aficamten

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

cardiovascular

Editor's Picks